JP2015091825A5 - - Google Patents

Download PDF

Info

Publication number
JP2015091825A5
JP2015091825A5 JP2014247340A JP2014247340A JP2015091825A5 JP 2015091825 A5 JP2015091825 A5 JP 2015091825A5 JP 2014247340 A JP2014247340 A JP 2014247340A JP 2014247340 A JP2014247340 A JP 2014247340A JP 2015091825 A5 JP2015091825 A5 JP 2015091825A5
Authority
JP
Japan
Prior art keywords
particle
particles
receptor antagonist
opioid receptor
hydrophilic additive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014247340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015091825A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015091825A publication Critical patent/JP2015091825A/ja
Publication of JP2015091825A5 publication Critical patent/JP2015091825A5/ja
Pending legal-status Critical Current

Links

JP2014247340A 2008-07-01 2014-12-05 オピオイド受容体アンタゴニスト含有の粒子および使用方法 Pending JP2015091825A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7724208P 2008-07-01 2008-07-01
US61/077,242 2008-07-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011516438A Division JP5985824B2 (ja) 2008-07-01 2009-06-15 オピオイド受容体アンタゴニスト含有の粒子および使用方法

Publications (2)

Publication Number Publication Date
JP2015091825A JP2015091825A (ja) 2015-05-14
JP2015091825A5 true JP2015091825A5 (enExample) 2015-07-16

Family

ID=41466277

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011516438A Active JP5985824B2 (ja) 2008-07-01 2009-06-15 オピオイド受容体アンタゴニスト含有の粒子および使用方法
JP2014247340A Pending JP2015091825A (ja) 2008-07-01 2014-12-05 オピオイド受容体アンタゴニスト含有の粒子および使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011516438A Active JP5985824B2 (ja) 2008-07-01 2009-06-15 オピオイド受容体アンタゴニスト含有の粒子および使用方法

Country Status (7)

Country Link
US (3) US20110250278A1 (enExample)
EP (1) EP2306829B1 (enExample)
JP (2) JP5985824B2 (enExample)
AU (1) AU2009265034B2 (enExample)
CA (1) CA2729582C (enExample)
ES (1) ES2620373T3 (enExample)
WO (1) WO2010002576A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109340A1 (en) 2010-03-01 2011-09-09 Nova Southeastern University Epinephrine nanop articles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20160045457A1 (en) 2005-09-09 2016-02-18 Ousama Rachid Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
EP2753321B1 (en) 2011-10-21 2021-12-15 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
EP2809263B1 (en) 2012-01-31 2017-08-23 Mitral Valve Technologies Sàrl Mitral valve docking devices, systems
MX2014013425A (es) * 2012-05-04 2015-08-14 Univ Chicago Biodisponibilidad de incrementos de metilnaltrexona oral con una formulacion basada en fosfatidilcolina.
CA3169368A1 (en) 2012-06-15 2014-01-09 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
PL2976072T3 (pl) 2013-03-22 2021-11-22 Nova Southeastern University Drobne cząstki epinefryny i sposoby ich stosowania do leczenia chorób reagujących na epinefrynę
CN104274414B (zh) * 2013-07-02 2018-03-09 天津康鸿医药科技发展有限公司 一种甲基纳曲酮复合物、口服片剂及其制备方法
MX2017000141A (es) * 2014-07-03 2017-04-25 Pfizer Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.
WO2019156904A1 (en) * 2018-02-08 2019-08-15 Taiwanj Pharmaceuticals Co., Ltd. Pharmaceutical formulation for a solid dosage form of opioid receptor antagonists
US20210128549A1 (en) * 2018-02-28 2021-05-06 Celista Pharmaceuticals Llc Oxycodone and methylnaltrexone multiparticulates and suspensions containing them
KR20210080429A (ko) 2018-10-19 2021-06-30 노바 사우쓰이스턴 유니버시티 피에이치 조절 부형제 및 침투 향상제를 포함하는 설하 에피네프린 조성물 및 그의 사용 방법
US20230201369A1 (en) * 2020-04-29 2023-06-29 The Texas A&M University System Naloxone nanoparticle compositions and methods thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1420015B1 (de) 1959-10-16 1971-08-26 Boehringer Sohn Ingelheim 2'-Hydroxy-5,9-dimethyl-6,7-benzomorphane
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4311833A (en) 1979-03-06 1982-01-19 Daicel Chemical Industries Ltd. Process for preparing ethylcarboxymethylcellulose
US4377568A (en) 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4457907A (en) 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
US4518433A (en) 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4462839A (en) 1983-06-16 1984-07-31 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
JPS6229515A (ja) 1985-07-30 1987-02-07 Shinjiro Tsuji 硬カプセル剤のフイルムコ−テイング方法
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5597564A (en) 1986-08-28 1997-01-28 Enzacor Properties Limited Method of administering a microgranular preparation to the intestinal region of animals
AU604052B2 (en) 1986-08-28 1990-12-06 Enzacor Properties Limited Animal growth promotant
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5270328A (en) 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
ES2109362T3 (es) 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
AU4198793A (en) * 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
CA2086631C (en) 1992-12-22 1998-10-06 J. Gabriel Michael Oral administration of immunologically active biomolecules and other therapeutic proteins
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5614222A (en) 1994-10-25 1997-03-25 Kaplan; Milton R. Stable aqueous drug suspensions and methods for preparation thereof
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
ES2114502B1 (es) 1996-07-29 1999-07-01 Univ Santiago Compostela Aplicacion de nanoparticulas a base de polimeros hidrofilicos como formas farmaceuticas.
AU4414497A (en) * 1996-09-13 1998-04-02 University Technology Corporation Biocompatible cationic detergents and uses therefor
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
IL148411A0 (en) * 1999-08-31 2002-09-12 Gruenenthal Chemie Delayed-action form of administration containing tramadol saccharinate
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
CA2408106A1 (en) * 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
DE60234183D1 (de) 2001-06-05 2009-12-10 Univ Chicago Verwendung von methylnaltrexon zur behandlung von immunsuppression
SI1436012T1 (en) 2001-10-18 2018-03-30 Nektar Therapeutics Polymer conjugates of opioid antagonists
CN1652752A (zh) * 2002-03-14 2005-08-10 欧罗赛铁克股份有限公司 盐酸纳曲酮组合物
ES2528631T3 (es) * 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
MXPA05010821A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
JP2006522817A (ja) * 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ,インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
WO2004098564A2 (en) * 2003-05-02 2004-11-18 The Board Of Trustees Of The University Of Illinois Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2007053194A2 (en) 2005-06-03 2007-05-10 The University Of Chicago Modulation of cell barrier dysfunction
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20080075768A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
TW200815451A (en) 2006-08-04 2008-04-01 Wyeth Corp 6-carboxy-normorphinan derivatives, synthesis and uses thereof
US20080113030A1 (en) 2006-11-09 2008-05-15 Ching-Fen Hsiao Sustained release tamsulosin formulations

Similar Documents

Publication Publication Date Title
JP2015091825A5 (enExample)
JP2011526898A5 (enExample)
JP2015521988A5 (enExample)
JP2014504630A5 (enExample)
WO2016064082A3 (ko) 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
JP2015205922A5 (enExample)
JP2014218522A5 (enExample)
HRP20250250T1 (hr) Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji
PH12013500252A1 (en) Fabric treatment compositions comprising targeted benefit agents
PH12014500305A1 (en) Benefit agent delivery particles comprising non-ionic polysaccharides
HRP20220759T1 (hr) Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti
MX362838B (es) Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
JP2017106010A5 (enExample)
WO2015091885A3 (en) Microcapsules with polymeric coating comprising a lipid and an active agent
HK1203815A1 (en) Pharmaceutical compositions and methods for their preparation
JP2016515523A5 (enExample)
PH12014502191A1 (en) Capsule disintegrable in large-intestine-specific manner
EP3223906A4 (en) Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
MX2017000041A (es) Formulaciones de liberacion inmediata disuasivas de abuso que comprenden polisacaridos no celulosicos.
EP3706713A4 (en) PHARMACEUTICAL COMPOSITIONS, METHOD OF MANUFACTURING THEREOF, INCLUDING SIZING OF LIPID VESICLE PARTICLES, AND USES
CN110139863A (zh) 作为雌激素受体降解剂的吲哚并取代哌啶类化合物
PH12019500947B1 (en) Pharmaceutical compositions and uses thereof
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE
JP2015508411A5 (enExample)
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer